RetinalGenix Technologies Inc. (RTGN)

USD 53.0

(88.0%)

Total Liabilities Summary of RetinalGenix Technologies Inc.

  • RetinalGenix Technologies Inc.'s latest annual total liabilities in 2023 was 1.4 Million USD , up 31.46% from previous year.
  • RetinalGenix Technologies Inc.'s latest quarterly total liabilities in 2024 Q2 was 1.89 Million USD , up 20.96% from previous quarter.
  • RetinalGenix Technologies Inc. reported annual total liabilities of 1.06 Million USD in 2022, up 127.71% from previous year.
  • RetinalGenix Technologies Inc. reported annual total liabilities of 469.62 Thousand USD in 2021, up 232.05% from previous year.
  • RetinalGenix Technologies Inc. reported quarterly total liabilities of 1.56 Million USD for 2024 Q1, up 11.63% from previous quarter.
  • RetinalGenix Technologies Inc. reported quarterly total liabilities of 1.77 Million USD for 2023 Q2, up 17.76% from previous quarter.

Annual Total Liabilities Chart of RetinalGenix Technologies Inc. (2023 - 2018)

Historical Annual Total Liabilities of RetinalGenix Technologies Inc. (2023 - 2018)

Year Total Liabilities Total Liabilities Growth
2023 1.4 Million USD 31.46%
2022 1.06 Million USD 127.71%
2021 469.62 Thousand USD 232.05%
2020 141.43 Thousand USD 367.56%
2019 30.24 Thousand USD 0.0%
2018 - USD 0.0%

Peer Total Liabilities Comparison of RetinalGenix Technologies Inc.

Name Total Liabilities Total Liabilities Difference
Acutus Medical, Inc. 54.83 Million USD 97.436%
Biotricity, Inc. 35.91 Million USD 96.086%
Cell MedX Corp. 872.57 Thousand USD -61.11%
Dynatronics Corporation 11.78 Million USD 88.066%
Nemaura Medical Inc. 26.37 Million USD 94.67%
PetVivo Holdings, Inc. 2.42 Million USD 42.131%
Sonendo, Inc. 49.74 Million USD 97.174%
Telesis Bio, Inc. 40.87 Million USD 96.561%
Talis Biomedical Corporation 29.22 Million USD 95.19%
Viveve Medical, Inc. 10.84 Million USD 87.04%